Literature DB >> 26477275

[Supportive care for malignant ascites in palliative phase: Place of paracentesis and diuretics].

Vincent Gamblin1, Arlette Da Silva2, Stéphanie Villet2, Farid El Hajbi3.   

Abstract

Malignant ascites, occurring in advanced stages of cancer, is linked with poor prognosis and can cause invalidating symptoms. Physiopathological mechanisms of ascites formation are complex and have yet to be fully elucidated. In most cases, ascites is due to peritoneal carcinomatosis in which vascular permeability is enhanced by VEGF production while lymphatic drainage decreases. Ascites can also be secondary to portal hypertension, for example in case of multiple liver metastases, or due to lymphatic obstruction. While paracentesis and diuretics are commonly used, their efficiency has never been compared in a randomized controlled study. Paracentesis brings immediate but temporary relief in over 90% of cases, and implies multiple hospitalizations. Literature reports ascites control by aldosterone alone or in association with furosemide. But, available data is controversial, and there is no predictive factor to identify patients that respond to diuretic treatment. The indication of diuretic treatment is left to the appreciation of physicians. Existing recommendations are old, and practices influenced by results obtained in non-neoplastic ascites. Additional evidences are required before guidelines can be established for the palliative management of malignant ascites.
Copyright © 2015 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Ascite maligne; Diuretics; Diurétiques; Malignant ascites; Paracentesis; Paracentèse

Mesh:

Substances:

Year:  2015        PMID: 26477275     DOI: 10.1016/j.bulcan.2015.09.002

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  2 in total

1.  Effect of Glycyrrhiza on the Diuretic Function of Euphorbia kansui: An Ascites Mouse Model.

Authors:  Ya Lin; Yanqiong Zhang; Erxin Shang; Wenfang Lai; Hongwei Zhu; Yuhua Fang; Qingxia Qin; Haiyu Zhao; Na Lin
Journal:  Evid Based Complement Alternat Med       Date:  2016-05-09       Impact factor: 2.629

Review 2.  Drainage of malignant ascites: patient selection and perspectives.

Authors:  Maciej Stukan
Journal:  Cancer Manag Res       Date:  2017-04-12       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.